Daniel Kremens (Sidney Kimmel Medical College, Thomas Jefferson University) discusses his recently published article co-authored with Stuart Isaacson, entitled: Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions. In this report, they explore the pathophysiology, symptomology, diagnosis and impact of Parkinson's disease psychosis (PDP), the role of serotonin signaling within PDP, and examine the current standard of care for treatment for the condition. The full article can be viewed here. Questions 1. How does Parkinson’s disease psychosis (PDP) differ from other psychotic disorders? (0:11) 2. What are the pathophysiological mechanisms underlying the development of PDP? (1:12) 3. What is the major limitation of atypical antispychotic drugs in treating patients with PDP? (2:32) 4. What clinical evidence supports the use of pimavenserin for PDP? (3:29) Speaker disclosures: Daniel Kremens has worked as a consultant for ACADIA, Teva, GE Healthcare, US WorldMeds, Impax, UCB, Kyowa, Acorda, Sunovion, St. Jude Medical, Adamas, Neurocrine and Prexton Therapeutics; received speaker’s honoraria for ACADIA, Teva, US WorldMeds, Impax, and UCB; and received research funding from Civitas and Enterin. Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018, with support from ACADIA Pharmaceuticals Inc.